|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
In December 2019 a new kind of virus was identified in China as the responsible of severe acute respiratory syndrome (SARS) and interstitial pneumonia. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) quickly spread around the world and in February 2020 became a pandemia in Europe. No pharmacological treatment is actually licensed for the SARS-CoV2 infection and at the current state of art there is a lack of data about the clinical management of the coronavirus 2019 disease (COVID-19). The aim of this observational study is to collect the data and the outcomes of COVID-19 patients admitted in the H. Sacco Respiratory Unit treated according to the Standard Operating Procedures and the Good Clinical Practice.
Description: Data collection about the real life management of patients affected by SARS-CoV-2 infection with acute respiratory distress syndromeMeasure: Real life data of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection Time: 1-6 months
Description: How many patients died during the hospitalizationMeasure: in-hospital mortality Time: 1 month
Description: How many patients died 30 days after the dischargeMeasure: 30 days mortality Time: 1 month
Description: How many patients died 6 months after the dischargeMeasure: 6 months mortality Time: 6 months
Description: How many patients were intubated during the hospitalizationMeasure: Intubation rate Time: 7 days
Description: How many days/hours from admittance to intubationMeasure: Time to Intubation Time: 7 days
Description: How many days/hours from admittance to the start of non invasive ventilation or CPAP therapyMeasure: Time to ventilation Time: 7 days
Description: How many days/hours from the start of non invasive ventilation or CPAP therapy to the intubationMeasure: Non invasive to Invasive time Time: 7 days
Description: How many patients were healed from the infection and dischargedMeasure: Recovery rate Time: 1 month
Description: How many patients underwent re-infection after previous recovery from COVID19Measure: Recurrence rate Time: 1 month
Description: Assessment of the risk factors for the infection and the admission to the hospitalMeasure: Risk factor for COVID19 Time: retrospective
Description: What serological parameter could be used as predictor of good or negative prognosis.Measure: Blood tests and outcome Time: 1 month
Description: Impact of antiviral therapy on the clinical course of the diseaseMeasure: Antiviral therapy Time: 1 month
Description: Assessment of bacterial, fungal or other coinfections rateMeasure: Coinfections Time: 1 month
Description: Impact of radiological findings on the clinical course and the outcomeMeasure: Radiological findings Time: 1 month
Description: Impact of ultrasound findings on the clinical course and the outcomeMeasure: Ultrasound findings Time: 1 month
Description: Assessment of the evidence of myocardial injury in covid19+ patientsMeasure: Myocardial injury Time: 1 month
Description: impact of standard therapeutic operating procedures (eg enteral nutrition, hydration, drugs) on the clinical course.Measure: Medical management Time: 1 month
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports